Kurt H.  Kruger net worth and biography

Kurt Kruger Biography and Net Worth

Mr. Kruger has enjoyed a 30-year career in Medical Technology. His deep involvement in the field has ranged from product design and development as a biomedical engineer to raising capital for, and following, publicly traded medical product companies as an equities research analyst. As a marketing manager at Guidant, now a part of Boston Scientific, he developed the launch plans for the first-ever implantable defibrillator. As a securities analyst he showed perspicuity leading Hambrecht & Quist in providing venture funds for, and then taking public, Ventritex, which was later acquired by St. Jude Medical. After Hambrecht & Quist, Kurt worked as an analyst for Montgomery Securities and Bank of America. Across 20 years of research work, Kurt has overseen the IPOs of over 30 medical products companies, including leadership of the Life Sciences banking effort for WR Hambrecht & Co. Mr. Kruger received a Sc.B. degree in Biomedical Engineering from Brown University; a Master’s degree in Bioengineering from the University of Michigan and a business degree (S.M.) from the Sloan School at the Massachusetts Institute of Technology (MIT). He also completed the premedical post-baccalaureate program at Columbia University.

What is Kurt H. Kruger's net worth?

The estimated net worth of Kurt H. Kruger is at least $2,970.00 as of December 29th, 2020. Mr. Kruger owns 10,000 shares of Qualigen Therapeutics stock worth more than $2,970 as of April 26th. This net worth estimate does not reflect any other investments that Mr. Kruger may own. Learn More about Kurt H. Kruger's net worth.

How do I contact Kurt H. Kruger?

The corporate mailing address for Mr. Kruger and other Qualigen Therapeutics executives is 2042 Corte Del Nogal, Carlsbad CA, 92011. Qualigen Therapeutics can also be reached via phone at (760) 918-9165 and via email at [email protected]. Learn More on Kurt H. Kruger's contact information.

Has Kurt H. Kruger been buying or selling shares of Qualigen Therapeutics?

Kurt H. Kruger has not been actively trading shares of Qualigen Therapeutics within the last three months. Learn More on Kurt H. Kruger's trading history.

Who are Qualigen Therapeutics' active insiders?

Qualigen Therapeutics' insider roster includes Amy Broidrick (EVP), Kurt Kruger (Director), and Michael Poirier (CEO). Learn More on Qualigen Therapeutics' active insiders.

Kurt H. Kruger Insider Trading History at Qualigen Therapeutics

See Full Table

Kurt H. Kruger Buying and Selling Activity at Qualigen Therapeutics

This chart shows Kurt H. Kruger's buying and selling at Qualigen Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Qualigen Therapeutics Company Overview

Qualigen Therapeutics logo
Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Read More

Today's Range

Now: $0.29
Low: $0.29
High: $0.32

50 Day Range

MA: $0.40
Low: $0.30
High: $0.58

2 Week Range

Now: $0.29
Low: $0.28
High: $1.26

Volume

9,116 shs

Average Volume

60,789 shs

Market Capitalization

$1.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A